» Articles » PMID: 16968166

Human Mesenchymal Stem Cells Induce T Cell Anergy and Downregulate T Cell Allo-responses Via the TH2 Pathway: Relevance to Tissue Engineering Human Heart Valves

Overview
Journal Tissue Eng
Date 2006 Sep 14
PMID 16968166
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

To generate an ''off the shelf'' tissue-engineered heart valve, the cells would need to be of allogeneic origin. Here, we report the possibility of using human bone marrow-derived mesenchymal stem cells (MSCs) as a suitable allogeneic cell source for tissue-engineered heart valves. Proliferative responses of primary and primed CD4+ T cells to allogeneic MSCs were examined. A protein microarray system was used to detect soluble factors from supernatants collected from the T cell assays. MSCs are poor stimulators of primary and primed CD4+ T cell proliferation, despite provision of B7-1 trans-co-stimulation. MSCs not only directly inhibited primary and primed T cell responses to allogeneic peripheral blood mononuclear cells (PBMCs), but 24-h pre-culture of T cells with MSCs suppressed subsequent T cell proliferative responses to allogeneic PBMCs in a contact-dependent manner. Analysis of supernatants revealed a distinctly different cytokine profile after co-culture of T cells with MSCs than with PBMCs or endothelial cells. Pro-inflammatory Th1 cytokines interleukin (IL)-1alpha and beta, interferon (IFN)gamma, and tumor necrosis factor (TNF)alpha were downregulated, whereas, anti-inflammatory Th2 cytokines IL-3, IL-5, IL-10, and IL-13 and the Th2 chemokine I-309, a chemoattractant for regulatory T cells, were upregulated. Further analysis revealed that after co-culture with MSCs, the T cells exhibited a regulatory phenotype (CD4+ CD25(lo) CD69(lo) FoxP3+). MSCs downregulate T cell responses through direct contact and secretion of anti-inflammatory and tolerogenic cytokines, which may involve the recruitment of regulatory T cells. This implies that allogeneic MSCs could be a suitable cell source for tissue engineering a heart valve.

Citing Articles

Mesenchymal stem cells as future treatment for cardiovascular regeneration and its challenges.

Seow K, Ling A Ann Transl Med. 2024; 12(4):73.

PMID: 39118948 PMC: 11304428. DOI: 10.21037/atm-23-1936.


Application of Exosomes-Derived Mesenchymal Stem Cells in Treatment of Fungal Diseases: From Basic to Clinical Sciences.

Ghasemian S Front Fungal Biol. 2023; 2:736093.

PMID: 37744094 PMC: 10512299. DOI: 10.3389/ffunb.2021.736093.


Canine Mesenchymal-Stem-Cell-Derived Extracellular Vesicles Attenuate Atopic Dermatitis.

Cho B, Kim S, Kim S, Rhee B, Yoon J, Lee J Animals (Basel). 2023; 13(13).

PMID: 37444013 PMC: 10339941. DOI: 10.3390/ani13132215.


Umbilical cord-mesenchymal stem cells induce a memory phenotype in CD4 T cells.

Sengun E, Wolfs T, van Bruggen V, van Cranenbroek B, Simonetti E, Ophelders D Front Immunol. 2023; 14:1128359.

PMID: 37409122 PMC: 10318901. DOI: 10.3389/fimmu.2023.1128359.


Mesenchymal stem cells can prevent or promote the progression of colon cancer based on their timing of administration.

Hu W, Wang W, Jiang X, Wang Z, Lin R J Transl Med. 2023; 21(1):227.

PMID: 36978120 PMC: 10045613. DOI: 10.1186/s12967-023-04028-3.